NewAmsterdam Pharma News and Activities
Presence
Headquarters: Netherlands
NewAmsterdam Pharma is a company listed under the stock ticker NAMS (NL).
Executives
View the org chart displaying its 31 main executives
Most searched biographies at NewAmsterdam Pharma
- Michael Davidson, Chief Executive Officer and Director
- Wouter Joustra, Director
- Janneke Van Der Kamp, Director
Popular executive movements at NewAmsterdam Pharma
- Louise Kooij, Chief Accounting Officer, will leave the company on Aug. 31, 2026 (posted on April 29 2026).
Create your alert
to follow the executive moves at NewAmsterdam Pharma.
Pharmaceuticals
NewAmsterdam Pharma has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by NewAmsterdam Pharma
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease | NewAmsterdam Pharma Company
- NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares | NewAmsterdam Pharma Company N.V.
- NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients | NewAmsterdam Pharma Company N.V.
- View more press releases Close
Social media about NewAmsterdam Pharma
- NewAmsterdam Pharma on Wikipedia, Google News & Yahoo Finance
- NewAmsterdam Pharma on LinkedIn, X (Twitter) & YouTube
